Sex-Based Disparities Among Cancer Clinical Trial Participants.


Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
01 02 2020
Historique:
received: 31 05 2019
revised: 15 07 2019
accepted: 17 07 2019
pubmed: 28 7 2019
medline: 11 8 2020
entrez: 28 7 2019
Statut: ppublish

Résumé

Landmark investigation two decades ago demonstrated sex-based disparities among participants in cancer cooperative group trials. Although federal efforts have aimed to improve representation of female patients in government-sponsored research, less is known about sex disparities in the broader landscape of modern oncologic randomized controlled trials. Using ClinicalTrials.gov, we identified randomized controlled trials related to colorectal or lung cancer (the two most common non-sex-specific disease sites). Among the 147 included trials, the proportion of female patients enrolled on trial was on average 6.8% (95% confidence interval = -8.8% to -4.9%) less than the proportion of female patients in the population by disease site (P < .001). Whereas no statistically significant underrepresentation of women was noted within the 26 cooperative group trials, sex disparities were markedly heightened for the 121 noncooperative-group-sponsored trials. Furthermore, underrepresentation of women did not improve with time. Future efforts should therefore focus on addressing these pervasive sex-based enrollment disparities beyond cooperative group trials alone.

Identifiants

pubmed: 31350545
pii: 5539753
doi: 10.1093/jnci/djz154
pmc: PMC7019091
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-213

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Références

JAMA Oncol. 2019 Jun 3;:
pubmed: 31158272
Cancer. 2009 Jul 15;115(14):3293-301
pubmed: 19507175
JAMA. 2004 Jun 9;291(22):2720-6
pubmed: 15187053
J Oncol Pract. 2013 Mar;9(2):e40-7
pubmed: 23814523
N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
J Clin Oncol. 2016 Nov 20;34(33):3992-3999
pubmed: 27646951
J Clin Oncol. 2008 Nov 20;26(33):5458-64
pubmed: 18955452
N Engl J Med. 2012 Aug 23;367(8):687-90
pubmed: 22913678

Auteurs

Ethan B Ludmir (EB)

The University of Texas MD Anderson Cancer Center, Houston, TX.

C David Fuller (CD)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Shalini Moningi (S)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Walker Mainwaring (W)

Baylor College of Medicine, Houston, TX.

Timothy A Lin (TA)

The University of Texas MD Anderson Cancer Center, Houston, TX.
Baylor College of Medicine, Houston, TX.

Austin B Miller (AB)

The University of Texas Health Science Center, Houston, TX.

Amit Jethanandani (A)

The University of Texas MD Anderson Cancer Center, Houston, TX.
The University of Tennessee Health Science Center, Memphis, TN.

Andres F Espinoza (AF)

Baylor College of Medicine, Houston, TX.

Vivek Verma (V)

Allegheny Health Network Cancer Institute, Pittsburgh, PA.

Benjamin D Smith (BD)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Grace L Smith (GL)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Noam A VanderWalde (NA)

West Cancer Center and Research Institute, Memphis, TN.

Emma B Holliday (EB)

The University of Texas MD Anderson Cancer Center, Houston, TX.

B Ashleigh Guadagnolo (BA)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Thomas E Stinchcombe (TE)

Duke Cancer Institute, Durham, NC.

Reshma Jagsi (R)

University of Michigan, Ann Arbor, MI.

Daniel R Gomez (DR)

The University of Texas MD Anderson Cancer Center, Houston, TX.
Memorial Sloan Kettering Cancer Center, New York, NY.

Bruce D Minsky (BD)

The University of Texas MD Anderson Cancer Center, Houston, TX.

Claus Rödel (C)

University of Frankfurt, Frankfurt, Germany.
German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Frankfurt, Germany.
Frankfurt Cancer Institute, Frankfurt, Germany.

Emmanouil Fokas (E)

University of Frankfurt, Frankfurt, Germany.
German Cancer Research Center, Heidelberg, Germany.
German Cancer Consortium, Frankfurt, Germany.
Frankfurt Cancer Institute, Frankfurt, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH